N-Ethylhexedrone

N-Ethylhexedrone (also known as α-ethylaminohexiophenone, α-EAHP, α-ethylamino-caprophenone, N-ethylnorhexedrone, Ethylnorhexedrone, Norhexedrone, Ethylhexedrone, hexen, and NEH) is a stimulant of the cathinone class that acts as a norepinephrine–dopamine reuptake inhibitor (NDRI) with IC50 inhibition values of 0.0978 and 0.0467 μM, respectively (97 nM and 46 nM). N-Ethylhexedrone was first mentioned in a series of patents by Boehringer Ingelheim in the 1960s which led to the development of the better-known drug methylenedioxypyrovalerone (MDPV). Since the mid-2010s, N-ethylhexedrone has been sold online as a designer drug. In 2018, N-ethylhexedrone was the second most common drug of the cathinone class to be identified in Drug Enforcement Administration seizures. N-Ethylhexedrone was first synthesized by Boehringer Ingelheim in 1964. It appears to have emerged on the online research chemical market in late 2015. It is an example of a novel psychoactive substance specifically chosen to mimic the features of prohibited substances and bypass drug laws. It is one of a number of substances collectively referred to as "bath salts". User reports characterize N-ethylhexedrone as having euphoric stimulant effects comparable to those of crack cocaine and α-PVP-type compounds, particularly when they are insufflated or vaporized. Like other substituted cathinones, N-ethylhexedrone has gained notoriety for its association with compulsive redosing and addictive behaviors when abused.